Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.11), $0.07 better than the analyst estimate of ($1.18).

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens as Pivotal Trial Advances
• Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue